COVID-19 vaccine sales boosted Pfizer earnings well past fourth-quarter expectations, but the drugmaker has set a lower-than-expected bar for 2022.

Rock 96.7 logo
Get our free mobile app

Pfizer's annual forecasts for both earnings and revenue fall short of analyst expectations even as the drugmaker expects another robust year of sales from its vaccine, Comirnaty, and its new coronavirus treatment, Paxlovid.

Pfizer expects Comirnaty to bring in another $32 billion in sales in 2022, while Wall Street is looking for more than $34 billion.

Both the company and the Street expect another $22 billion in sales from Paxlovid, which received U.S. authorization shortly before Christmas.

45 Pictures Of Casper's Logan Wilson's NFL Action

The one time player at Natrona County High School and University of Wyoming has made quite the impact over the last 2 years in the NFL. Including being a big part of the defense that has lead the Cincinnati Bengals to their first Super Bowl in over 30 year.


More From Rock 96.7